Group 1: Investor Relations Activity Overview - The investor relations activity was a roadshow held on September 20, 2024, at the Shenzhen Stock Exchange [2] - Attendees included investors from the pharmaceutical and biotechnology sectors [2] - Company representatives included Ms. Tang Menghua, the director and deputy general manager [2] Group 2: Key Questions and Responses - Difference between products: The company clarified the distinctions between freeze-dried recombinant type III humanized collagen fibers and injectable solutions in terms of form, specifications, and usage [4] - International market plans: The company is focusing on three categories: medical devices, cosmetics, and raw materials, with initial overseas efforts in Southeast Asia and Japan/Korea through partnerships with major international firms [4] - Share repurchase considerations: Currently, there are no plans for stock buybacks, despite inquiries about their potential to enhance share value [4] - Imitation of products: The company holds a leading position in the recombinant humanized collagen field, with multiple patents protecting its core technologies and products [4][5] Group 3: Product Advantages - The recombinant humanized collagen has four core advantages: 1. Resolves collagen's immunogenicity 2. Matches the amino acid sequence of human type III collagen 3. Features a flexible triple helix fiber structure with high solubility 4. Capable of industrial-scale production [5] Group 4: Future Development Strategy - The company aims to leverage synthetic biology and structural biology for innovative research on functional proteins, focusing on a complete industrial chain for various types of collagen and antiviral proteins [6] - Plans to provide comprehensive solutions for tissue repair and regeneration in the healthcare sector, aspiring to become a leading innovative biomaterials enterprise [6]
锦波生物(832982) - 关于投资者关系活动记录表的公告